Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
IPO Year:
Exchange: AMEX
Website: senseonics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2025 | $9.00 | Hold | Stifel |
| 8/27/2025 | $1.50 | Overweight | Barclays |
| 7/15/2025 | $1.25 | Buy | TD Cowen |
| 6/2/2025 | $1.10 | Buy | H.C. Wainwright |
| 4/10/2025 | $2.00 | Outperform | Mizuho |
| 7/19/2023 | $0.50 | Underperform | Jefferies |
| 8/19/2021 | $6.00 | Buy | HC Wainwright & Co. |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4/A - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
SD - Senseonics Holdings, Inc. (0001616543) (Filer)
S-8 - Senseonics Holdings, Inc. (0001616543) (Filer)
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
10-Q - Senseonics Holdings, Inc. (0001616543) (Filer)
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
424B5 - Senseonics Holdings, Inc. (0001616543) (Filer)
424B5 - Senseonics Holdings, Inc. (0001616543) (Filer)
DEFR14A - Senseonics Holdings, Inc. (0001616543) (Filer)
DEFA14A - Senseonics Holdings, Inc. (0001616543) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
Fastest customizable press release news feed in the world
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. Senseonics will be hosting an analyst event to discuss the Eversense 365 platform, as well as an oral presentation on the ADA program discussing real world evidence of the world's first and only one year CGM system. Analyst Event DetailsSenseonics
Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of c
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to transform lives in the global diabetes community, announced that it has entered into a Second Amendment to the Loan and Security Agreement with Hercules Capital, Inc. (NYSE:HTGC). The Second Amendment increases the maximum borrowing capacity under the existing facility from $100 million to $140 million. In addition to $35 million of borrowings currently outstanding under the existing facility, the amended facility will: Provide for $20 million of near-term loan commitments
GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will hold a conference call to review the Company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseon
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $5.00 per share, and in lieu of common stock, to certain investors, pre-funded warrants to purchase 8,000,000 shares of common stock at a purchase price of $4.999 per pre-funded warrant share, which equals the public offering price per share of the common stock less the $0.001 exercise pr
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and, to certain investors, pre-funded warrants to purchase its common stock in lieu thereof. In connection with the proposed offering, Senseonics also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of
Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, April 29, 2026 /CNW/ -- Equity-Insider.com News Commentary – Here's the quiet shift in medtech right now: the global medical imaging market is on track to grow from $41.64 billion in 2024 to $67.87 billion by 2034[1], and capital has stopped chasing every shiny promise. That pressure got real in April, when the FDA advanced its real-world evidence framework for medical devices[2], lining regulators and payers up around documented performance instead of trial-stage pitches. Five names keep showing up in that conversation: VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Senseonics (NASDAQ:SENS), TransMedics Group (NASDAQ:TMDX),
The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out Eversense 365 doubles sensor lifespan from the previously available Eversense E3, extending the unique features and benefits of long-term implantable CGM use from six months to a full year GERMANTOWN, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the first European launch of the Eversense® 365 CGM
Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Live Leadership Updates
Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00
Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50
TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25
H.C. Wainwright resumed coverage of Senseonics with a rating of Buy and set a new price target of $1.10
Mizuho initiated coverage of Senseonics with a rating of Outperform and set a new price target of $2.00
Jefferies initiated coverage of Senseonics with a rating of Underperform and set a new price target of $0.50
HC Wainwright & Co. initiated coverage of Senseonics Holdings with a rating of Buy and set a new price target of $6.00
SVB Leerink downgraded Senseonics Holdings from Outperform to Market Perform and set a new price target of $3.00
SVB Leerink reiterated coverage of Senseonics Holdings with a rating of Outperform and set a new price target of $3.00 from $1.00 previously
Raymond James downgraded Senseonics Holdings from Market Perform to Underperform
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po
Live finance-specific insights
GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will hold a conference call to review the Company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseon
Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase
Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudite
Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from Ascensia Diabetes Care back to Senseonics GERMANTOWN, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights & Accomplishments: Generated revenue of $8.1 million in the third quarter of 2
GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will hold a conference call to review the Company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by na
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio
GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025. Management will hold a conference call to review the Company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by na
Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 GERMANTOWN, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.3 million in the first quarter of 2025CMS upda
GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Management will hold a conference call to review the Company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigat
Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients GERMANTOWN, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the fourth quarter ended December 31, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved and launched in the U.S. during 2024 as an integrated contin
This live feed shows all institutional transactions in real time.
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13D/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)